Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2023 16:05 ET | Source: Compass Pathways

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
December 07, 2023 07:00 ET | Source: Compass Pathways

Compass Pathways appoints Teri Loxam as Chief Financial Officer

LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
December 06, 2023 16:00 ET | Source: Compass Pathways

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
November 24, 2023 08:00 ET | Source: Compass Pathways

Compass Pathways to participate in upcoming Evercore investor conference

LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
November 15, 2023 04:00 ET | Source: Compass Pathways

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened...
November 02, 2023 07:00 ET | Source: COMPASS Pathways

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

Highlights: COMP360 Phase 3 pivotal program ongoing with expanding European clinical sitesSecured up to $285 million private placement financing with $125 million upfrontCash position at September 30,...
October 26, 2023 08:00 ET | Source: COMPASS Pathways

COMPASS Pathways announces CFO transition

LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based...
October 24, 2023 16:01 ET | Source: COMPASS Pathways

COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023

LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
September 18, 2023 16:31 ET | Source: COMPASS Pathways

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
September 06, 2023 04:00 ET | Source: COMPASS Pathways

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right